Advances in antiangiogenic treatment of small-cell lung cancer

References

• SchneiderBJKalemkerianGPPersonalized therapy of small cell lung cancerAdv Exp Med Biol201689014917426703804
   PubMed Web of Science ®Google Scholar
• MinamiTKijimaTKohmoSOvercoming chemoresistance of small-cell lung cancer through stepwise HER2-targeted antibody-dependent cell-mediated cytotoxicity and VEGF-targeted antiangiogenesisSci Rep20133266924036898
   PubMedGoogle Scholar
• FontaniniGLucchiMVignatiSAngiogenesis as a prognostic indicator of survival in non-small-cell lung carcinoma: a prospective studyJ Natl Cancer Inst199789128818869196255
   PubMed Web of Science ®Google Scholar
• ZhouCWuYLChenGBEYOND: a randomized, double-blind, placebo-controlled, multicenter, phase III study of first-line carboplatin/paclitaxel plus bevacizumab or placebo in chinese patients with advanced or recurrent nonsquamous non-small-cell lung cancerJ Clin Oncol201533192197220426014294
   PubMed Web of Science ®Google Scholar
• LucchiMMussiAFontaniniGFavianaPRibechiniAAngelettiCASmall cell lung carcinoma (SCLC): the angiogenic phenomenonEur J Cardiothorac Surg20022161105111012048093
   PubMed Web of Science ®Google Scholar
• SpigelDRWaterhouseDMLaneSLegennePBhattKEfficacy and safety of oral topotecan and bevacizumab combination as second-line treatment for relapsed small-cell lung cancer: an open-label multicenter single-arm phase II studyClin Lung Cancer201314435636323391616
   PubMedGoogle Scholar
• TrafalisDTAlifierisCStathopoulosGPSitarasNPhase II study of bevacizumab plus irinotecan on the treatment of relapsed resistant small cell lung cancerCancer Chemother Pharmacol201677471372226891956
   PubMedGoogle Scholar
• JalalSBedanoPEinhornLPaclitaxel plus bevacizumab in patients with chemosensitive relapsed small cell lung cancer: a safety, feasibility, and efficacy study from the Hoosier Oncology GroupJ Thorac Oncol20105122008201121102263
   PubMed Web of Science ®Google Scholar
• MountziosGEmmanouilidisCVardakisNPaclitaxel plus bevacizumab in patients with chemoresistant relapsed small cell lung cancer as salvage treatment: a phase II multicenter study of the Hellenic Oncology Research GroupLung Cancer201277114615022418242
   PubMedGoogle Scholar
• PujolJLLavoleAQuoixEFrench Cooperative Thoracic Intergroup (IFCT)French Cooperative Thoracic Intergroup IFCTRandomized phase II–III study of bevacizumab in combination with chemotherapy in previously untreated extensive small-cell lung cancer: results from the IFCT-0802 trialAnn Oncol201526590891425688059
   PubMed Web of Science ®Google Scholar
• PetrioliRRovielloGLaeraLCisplatin, etoposide, and bevacizumab regimen followed by oral etoposide and bevacizumab maintenance treatment in patients with extensive-stage small cell lung cancer: a single-institution experienceClin Lung Cancer2015166e229e23426072097
   PubMedGoogle Scholar
• SpigelDRTownleyPMWaterhouseDMRandomized phase II study of bevacizumab in combination with chemotherapy in previously untreated extensive-stage small-cell lung cancer: results from the SALUTE trialJ Clin Oncol201129162215222221502556
   PubMed Web of Science ®Google Scholar
• SpigelDRGrecoFAZubkusJDPhase II trial of irinotecan, carboplatin, and bevacizumab in the treatment of patients with extensive-stage small-cell lung cancerJ Thorac Oncol20094121555156019875975
   PubMedGoogle Scholar
• TiseoMBoniLAmbrosioFItalian multicenter phase III randomized study of cisplatin–etoposide with or without bevacizumab as first-line treatment in extensive stage small cell lung cancer (SCLC): GOIRC-AIFA FARM6PMFJM trialJ Clin Oncol201634Suppl abstr 8513
   Google Scholar
• SpigelDRHainsworthJDYardleyDATracheoesophageal fistula formation in patients with lung cancer treated with chemoradiation and bevacizumabJ Clin Oncol2010281434819901100
   PubMed Web of Science ®Google Scholar
• KimESSerurAHuangJPotent VEGF blockade causes regression of coopted vessels in a model of neuroblastomaProc Natl Acad Sci U S A20029917113991140412177446
   PubMed Web of Science ®Google Scholar
• AllenJWMoonJRedmanMSouthwest Oncology Group S0802: a randomized, phase II trial of weekly topotecan with and without ziv-aflibercept in patients with platinum-treated small-cell lung cancerJ Clin Oncol201432232463247025002722
   PubMed Web of Science ®Google Scholar
• Van CutsemETaberneroJLakomyRAddition of aflibercept to fluorouracil, leucovorin, and irinotecan improves survival in a phase III randomized trial in patients with metastatic colorectal cancer previously treated with an oxaliplatin-based regimenJ Clin Oncol201230283499350622949147
   PubMed Web of Science ®Google Scholar
• O’ReillyMSBoehmTShingYEndostatin: an endogenous inhibitor of angiogenesis and tumor growthCell19978822772859008168
   PubMed Web of Science ®Google Scholar
• ZhouZTZhouFXWeiQZouLYQinBFPengXSPhase II study of cisplatin/etoposide and endostar for extensive-stage small-cell lung cancerCancer Chemother Pharmacol20116841027103221327933
   PubMedGoogle Scholar
• LuSLiLLuoYA multicenter, open-label, randomized phase II controlled study of rh-endostatin (Endostar) in combination with chemotherapy in previously untreated extensive-stage small-cell lung cancerJ Thorac Oncol201510120621125654728
   PubMedGoogle Scholar
• MallJWPhilippAWMallWPollmannCLong-term survival of a patient with small-cell lung cancer (SCLC) following treatment with thalidomide and combination chemotherapyAngiogenesis200251–2111312549855
   PubMedGoogle Scholar
• DowlatiASubbiahSCooneyMPhase II trial of thalidomide as maintenance therapy for extensive stage small cell lung cancer after response to chemotherapyLung Cancer200756337738117328989
   PubMedGoogle Scholar
• LeeSMJamesLBuchlerTSneeMEllisPHackshawAPhase II trial of thalidomide with chemotherapy and as maintenance therapy for patients with poor prognosis small-cell lung cancerLung Cancer200859336436817920723
   PubMed Web of Science ®Google Scholar
• PujolJLBretonJLGervaisRPhase III double-blind, placebo-controlled study of thalidomide in extensive-disease small-cell lung cancer after response to chemotherapy: an intergroup study FNCLCC cleo04 IFCT 00-01J Clin Oncol200725253945395117761978
   PubMedGoogle Scholar
• LeeSMWollPJRuddRAnti-angiogenic therapy using thalidomide combined with chemotherapy in small cell lung cancer: a randomized, double-blind, placebo-controlled trialJ Natl Cancer Inst2009101151049105719608997
   PubMedGoogle Scholar
• YoungRJTinAWBrownNJJitlalMLeeSMWollPJAnalysis of circulating angiogenic biomarkers from patients in two phase III trials in lung cancer of chemotherapy alone or chemotherapy and thalidomideBr J Cancer201210661153115922353811
   PubMedGoogle Scholar
• AbramsTJLeeLBMurrayLJPryerNKCherringtonJMSU11248 inhibits KIT and platelet-derived growth factor receptor beta in preclinical models of human small cell lung cancerMol Cancer Ther20032547147812748309
   PubMed Web of Science ®Google Scholar
• HanJYKimHYLimKYA phase II study of sunitinib in patients with relapsed or refractory small cell lung cancerLung Cancer201379213714223182663
   PubMedGoogle Scholar
• AbdelraoufFSmitEHasanBSunitinib (SU11248) in patients with chemo naive extensive small cell lung cancer or who have a ‘chemosensitive’ relapse: a single-arm phase II study (EORTC-08061)Eur J Cancer201654353926716400
   PubMedGoogle Scholar
• ReadyNEPangHHGuLChemotherapy with or without maintenance sunitinib for untreated extensive-stage small-cell lung cancer: a randomized, double-blind, placebo-controlled Phase II Study-CALGB 30504 (Alliance)J Clin Oncol201533151660166525732163
   PubMed Web of Science ®Google Scholar
• SalamaJKGuLWangXPositive interaction between prophylactic cranial irradiation and maintenance sunitinib for untreated extensive-stage small cell lung cancer patients after standard chemotherapy: a secondary analysis of CALGB 30504 (ALLIANCE)J Thorac Oncol201611336136926723241
   PubMedGoogle Scholar
• SchneiderBJMaintenance sunitinib for extensive-stage small cell lung cancer: a new standard, an option or a step in the right direction?Transl Lung Cancer Res20154563563826629436
   PubMedGoogle Scholar
• Di MaioMBironzoPScagliottiGVRaising the bar for enthusiasm when looking at results of randomized phase II trials-the case of sunitinib in small-cell lung cancerTransl Lung Cancer Res201651899126958498
   PubMedGoogle Scholar
• SpigelDRGrecoFARubinMSPhase II study of maintenance sunitinib following irinotecan and carboplatin as first-line treatment for patients with extensive-stage small-cell lung cancerLung Cancer201277235936422560921
   PubMedGoogle Scholar
• SharmaNPennellNNickolichMPhase II trial of sorafenib in conjunction with chemotherapy and as maintenance therapy in extensive-stage small cell lung cancerInvest New Drugs201432236236824420556
   PubMedGoogle Scholar
• EllisPMJungneliusUZhangJFandiABeckRShepherdFA phase I study of pomalidomide (CC-4047) in combination with cisplatin and etoposide in patients with extensive-stage small-cell lung cancerJ Thorac Oncol20138442342823370364
   PubMedGoogle Scholar
• MatulonisUABerlinSIvyPCediranib, an oral inhibitor of vascular endothelial growth factor receptor kinases, is an active drug in recurrent epithelial ovarian, fallopian tube, and peritoneal cancerJ Clin Oncol200927335601560619826113
   PubMed Web of Science ®Google Scholar
• RamalingamSSBelaniCPMackPCPhase II study of Cediranib (AZD 2171), an inhibitor of the vascular endothelial growth factor receptor, for second-line therapy of small cell lung cancer (National Cancer Institute ≤7097)J Thorac Oncol2010581279128420559150
   PubMed Web of Science ®Google Scholar
• ArnoldAMSeymourLSmylieMNational Cancer Institute of Canada Clinical Trials Group Study BR.20Phase II study of vandetanib or placebo in small-cell lung cancer patients after complete or partial response to induction chemotherapy with or without radiation therapy: National Cancer Institute of Canada Clinical Trials Group Study BR.20J Clin Oncol200725274278428417878480
   PubMed Web of Science ®Google Scholar
• SanbornREPatelJDMastersGAA randomized, double-blind, phase 2 trial of platinum therapy plus etoposide with or without concurrent vandetanib (ZD6474) in patients with previously untreated extensive-stage small cell lung cancer: Hoosier Cancer Research Network LUN06-113Cancer Epub20169110.1002/cncr.30287
   PubMedGoogle Scholar
• HanJYKimHYLimKYHwangboBLeeJSA phase II study of nintedanib in patients with relapsed small cell lung cancerLung Cancer20169610811227133759
   PubMed Web of Science ®Google Scholar
• MallJWSchwenkWPhilippAWSerum vascular endothelial growth factor levels correlate better with tumour stage in small cell lung cancer than albumin, neuron-specific enolase or lactate dehydrogenaseRespirology2002729910211985730
   PubMed Web of Science ®Google Scholar
• UstunerZSaipPYasaseverVPrognostic and predictive value of vascular endothelial growth factor and its soluble receptors, VEGFR-1 and VEGFR-2 levels in the sera of small cell lung cancer patientsMed Oncol200825439439918317954
   PubMedGoogle Scholar
• CañadasITausÁVillanuevaXAngiopoietin-2 is a negative prognostic marker in small cell lung cancerLung Cancer201590230230626428740
   PubMedGoogle Scholar